By Michael Dabaie
Bristol Myers Squibb Co. shares were 3% higher to $67.22 in morning trading after a Phase 3 study in lymphoma met its main objective.
The company said before the market open that a Phase 3 study of Breyanzi as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma met its primary and key secondary objectives.
"We ambitiously designed the TRANSFORM trial to evaluate Breyanzi's potential in the second-line setting for patients with relapsed or refractory large B-cell lymphoma against the standard of care regimen of high-dose chemotherapy and autologous stem cell transplant," said Noah Berkowitz, senior vice president of hematology and cell therapy development for Bristol Myers.
This represents the first time a therapy has demonstrated benefit compared with high-dose chemotherapy and stem cell transplant in relapsed or refractory large B-cell lymphoma, Bristol Myers said.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires